ClinicalTrialsFinder
RecruitingPhase 1NCT07723833

A Study to Investigate the Relative Bioavailability and Safety of Different Oral Formulations of Elecoglipron in Healthy Participants

A Phase I, Randomized, Single-dose, Crossover, 2-Period, Open-Label Study to Assess the Relative Bioavailability and Safety of Different Oral Formulations of Elecoglipron in Healthy Participants

Sponsor

AstraZeneca

Enrollment

152 participants

Start Date

Jul 27, 2026

Study Type

INTERVENTIONAL

Conditions

Healthy Participants

Summary

The purpose of this study is to measure the pharmacokinetics (PK-how the body processes the study drug) of elecoglipron in healthy participants when taken by mouth as different formulations.

Eligibility

Min Age: 18 YearsMax Age: 55 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Elecoglipron Reference Formulation Dose A, a drug called Elecoglipron Reference Formulation Dose B, and others for people with healthy participants. The study is currently recruiting participants at 2 locations. People eligible for this study include aged 18 Years to 55 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGElecoglipron Reference Formulation Dose A

Elecoglipron tablets will be administered orally.

DRUGElecoglipron Test formulation 1 Dose A

Elecoglipron tablets will be administered orally.

DRUGElecoglipron Reference Formulation Dose B

Elecoglipron tablets will be administered orally.

DRUGElecoglipron Test formulation 1 Dose B

Elecoglipron tablets will be administered orally.

DRUGElecoglipron Test formulation 2 Dose A

Elecoglipron tablets will be administered orally.

DRUGElecoglipron Test formulation 2 Dose B

Elecoglipron tablets will be administered orally.

Locations(2)

Research Site

Glendale, California, United States

Research Site

Brooklyn, Maryland, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07723833

Related Trials

A Study to Investigate the Effect of AZD6234, AZD9550, and a Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Participants Living With Overweight or Obesity

NCT070136432 locations

A Study to Evaluate Different Oral Formulations of KT-621

NCT07823205

Study to Assess Tolerability of Injecting Larger Volumes (2-5 mL) Subcutaneously at Different Rates: Participant Experience and Acceptance

NCT07769489

IBI3042 Study in Healthy Participants and Overweight or Obese Participants

NCT07793019

A Study to Investigate Safety and Tolerability of mRNA-0184 Administered Subcutaneously in Healthy Participants

NCT06655870